Vortioxetine
وورتیوکستین
🧠 Nervous SystemMultimodal antidepressant
Market / country: 🇺🇸 USA
Trintellix (US)
🧮 Dose calculator
Major depressive disorder · Regimen source: FDA Trintellix · 2.1
- • May reduce to 5 mg if not tolerated. Screen for bipolar disorder before starting. FDA Trintellix · 2.1FDA Trintellix · 2.2
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity; MAOIs, within 14 days of stopping an MAOI or 21 days of stopping vortioxetine; linezolid or IV methylene blue. FDA Trintellix · 4
Warnings
- • Boxed warning: increased suicidal thoughts and behaviour in children and young adults; not approved in children. FDA Trintellix · Boxed Warning
Formulations
- 5 mg tablet — tablet 🇺🇸 USA FDA Trintellix · 3
- 10 mg tablet — tablet 🇺🇸 USA FDA Trintellix · 3
- 20 mg tablet — tablet 🇺🇸 USA FDA Trintellix · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Trintellix · 8.1
“Risk Summary Based on data from published observational studies, exposure to SSRIs or SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions (5.3) and Clinical Considerations ] .”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Trintellix · 8.2
“Risk Summary There is no information regarding the presence of vortioxetine in human milk, the effects on the breastfed infant, or the effects on milk production.”
- 👶 ChildrenDangerous / avoid
Boxed warning in the label about children. FDA Trintellix · Boxed Warning
“Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Trintellix · 8.5
“Serotonergic antidepressants have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions (5.7) ] .”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA204447
- DailyMed (FDA label)FDA Trintellix
- MedlinePlus (NIH)Vortioxetine
- WHO ATC/DDDN06AX26
- Darooyab (Iran)❌ None
🇮🇷 Not found in Iran list Darooyab · search
Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Trintellix · 3FDA Trintellix · 2.1FDA Trintellix · 2.2FDA Trintellix · 4FDA Trintellix · Boxed WarningFDA Trintellix · SPL approval / marketing categoryFDA Trintellix · 8.1FDA Trintellix · 8.2FDA Trintellix · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · search
- Clinical review⚠ Unverified